知柏地黄汤加减联合西药治疗小儿过敏性紫癜临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R725.5

基金项目:


Clinical Study on Modified Zhibai Dihuang Tang Combined with Western Medicine for Children with Allergic Purpura
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察知柏地黄汤加减联合西药治疗小儿过敏性紫癜阴虚火旺证的临床疗效。方法:采用随机数字表法将86 例过敏性紫癜患儿分为对照组与观察组各43 例。对照组给予常规西药治疗,观察组采用常规西药联合知柏地黄汤加减治疗。比较2 组治疗前后中医证候评分、T 淋巴细胞亚群(CD3+、CD4+、CD19+)、免疫球蛋白、炎症因子水平。比较2 组临床疗效及复发情况。结果:治疗后,观察组总有效率为93.02%,显著高于对照组74.42%(P<0.05)。治疗后,2 组皮肤紫癜、关节疼痛、腹痛、手足心热、两面颧红、低热盗汗、心烦少寐评分均较治疗前降低(P<0.05),且观察组中医证候评分低于对照组(P<0.05)。治疗后,2 组血清CD3+、CD4+水平较治疗前升高(P<0.05),CD19+水平降低(P<0.05),且观察组上述指标改善优于对照组(P<0.05);2 组血清免疫球蛋白A (IgA)、免疫球蛋白M (IgM)、免疫球蛋白G (IgG)、肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)、白细胞介素-12(IL-12) 水平均较治疗前降低(P<0.05),且观察组免疫球蛋白及炎症因子水平均低于对照组(P<0.05)。随访3 个月后,观察组复发率12.50%,低于对照组40.62%(P<0.05)。结论:知柏地黄汤加减联合西药治疗过敏性紫癜临床疗效显著,能够有效提高患儿免疫水平,降低炎症因子水平及复发率。

    Abstract:

    Abstract: Objective: To observe the clinical effect of the therapy of modified Zhibai Dihuang Tang combined with western medicine on children with allergic purpura with syndrome of vigorous fire due to yin deficiency. Methods:A total of 86 children with allergic purpura were randomly divided into the observation group and control group, with 43 cases in each group. The control group was treated with conventional western medicine,and the observation group was additionally treated with conventional western medicine combined with modified Zhibai Dihuang Tang. The Chinese medicine syndrome scores, T lymphocyte subsets,including CD3 +,CD4 +,and CD19 +,immunoglobulin and inflammatory factors were compared between the two groups before and after treatment. The clinical effects and recurrence were compared between the two groups. Results:After treatment,the observation group total effective rate was 93.02% were higher than control group 74.42%(P<0.05). After treatment,the scores of skin purpura,joint pain, abdominal pain,fever of palms and sole,hot flushes on the cheeks,low-grade fever and night sweats, vexation and restless sleep in the two groups were lower than those pre- treatment(P<0.05), and the scores of the above Chinese medicine syndromes in the control group were higher than those in the observation group(P<0.05). After treatment,compared with pre-treatment the serum levels of CD3+ and CD4+ in the two groups were increased(P<0.05),but the levels of CD19+ were decreased(P<0.05),and the improvement of the above levels in the observation group was better than that in the control group(P< 0.05);compared with those pre-treatment,the serum levels of immunoglobulin A(IgA),immunoglobulin M(IgM),immunoglobulin G(IgG),tumor necrosis factor-α(TNF-α),interleukin-4(IL-4) and interleukin-12 (IL- 12) were significantly decreased(P<0.05); in the control group the levels of immunoglobulin and inflammatory factors were higher than those in the observation group(P<0.05). After three months of follow- up,the observation group recurrence rate was 12.50% lower the control group 40.62%(P<0.05). Conclusion: The therapy of modified Zhibai Dihuang Tang combined with western medicine has a significant clinical effect on allergic purpura, which can effectively improve the immune level of children, reduce the levels of inflammatory factors and the recurrence rate.

    参考文献
    相似文献
    引证文献
引用本文

蔡亚丽.知柏地黄汤加减联合西药治疗小儿过敏性紫癜临床研究[J].新中医,2022,54(23):43-47

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-12-11
  • 出版日期:
文章二维码